Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Learning from the youngsters: ixekizumab in active ankylosing spondylitis

The COAST-V study published by Désirée van der Heijde and colleagues in The Lancet1 shows that ixekizumab, a monoclonal antibody that selectively targets interleukin (IL)-17A, is efficacious in patients with ankylosing spondylitis (also known as radiographic axial spondyloarthritis) who have previously been untreated with biological disease-modifying antirheumatic drugs (bDMARDs). Ixekizumab has already followed the other IL-17A antibody, secukinumab, in two other indications, psoriasis and psoriatic arthritis, and it seems likely that an approval for radiographic axial spondyloarthritis will follow on the basis of the evidence provided in this Article.

email